EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study

E Michael Lewiecki iD, Edward Czerwinski, Chris Recknor, Anna Strzelecka, Guillermo Valenzuela, Mary Lawrence, Stuart Silverman, Jose Cardona, Susan M Nattrass, Neil Binkley iD, Miriam Annett, Leny Pearman und 1 weitere

Journal of Bone and Mineral Research · 2023

DOI: 10.1002/jbmr.4877 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Mineral Research, 2023. Verfasst von E Michael Lewiecki und 12 weiteren Autor:innen. Beteiligte Einrichtung: New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Osteoporosis, Osteoporotic Fractures. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Radius Health, Inc, Radius Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC). The objective of this study was to evaluate the efficacy and safety of the abaloparatide microstructured transdermal system (abaloparatide-sMTS) as an alternative to the SC formulation. This phase 3, noninferiority study (NCT04064411) randomly assigned postmenopausal women with osteoporosis (N = 511) 1:1 to open-label abaloparatide administered daily via abaloparatide-sMTS or SC injection for 12 months. The primary comparison between treatment groups was the percentage change in lumbar spine bone mineral density (BMD) at 12 months, with a noninferiority margin of 2.0%. Secondary endpoints included percentage change in total hip and femoral neck BMD, bone turnover markers, dermatologic safety, and new clinical fracture incidence. At 12 months, percentage increase from baseline in lumbar spine BMD was 7.14% (SE: 0.46%) for abaloparatide-sMTS and 10.86% (SE: 0.48%) for abaloparatide-SC (treatment difference: −3.72% [95% confidence interval: −5.01%, −2.43%]). Percentage change in total hip BMD was 1.97% for abaloparatide-sMTS and 3.70% for abaloparatide-SC. Median changes from baseline at 12 months in serum procollagen type I N-terminal propeptide (s-PINP) were 52.6% for abaloparatide-sMTS and 74.5% for abaloparatide-SC. Administration site reactions were the most frequently reported adverse events (abaloparatide-sMTS, 94.4%; abaloparatide-SC, 70.5%). Incidence of serious adverse events was similar between groups. Mild or moderate skin reactions occurred with abaloparatide-sMTS with no identifiable risk factors for sensitization reactions. Few new clinical fractures occurred in either group. Noninferiority of abaloparatide-sMTS to abaloparatide-SC for percentage change in spine BMD at 12 months was not demonstrated; however, clinically meaningful increases from baseline in lumbar spine and total hip BMD were observed in both treatment groups. © 2023 Radius Health, Inc and The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). Abstract In postmenopausal women with osteoporosis, the least-squares mean percentage change (SE) from baseline in lumbar spine BMD at 12 months was 7.14% (0.46%) for daily transdermal abaloparatide and 10.86% (0.48%) for daily SC abaloparatide, with a treatment difference of −3.72% (95% CI: −5.01%, −2.43%). Clinically meaningful changes were also seen in total hip BMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalBone Density Conservation AgentsOsteoporosisOsteoporotic FracturesHumansFemalePostmenopauseBone DensityLumbar VertebraeMineralsParathyroid Hormone-Related ProteinCollagen Type I

Stichwörter der Autor:innen

ABALOPARATIDE-sMTSBONE MINERAL DENSITYBONE TURNOVER MARKERSFRACTUREOSTEOPOROSISTRANSDERMAL

Substanzen

Bone Density Conservation AgentsMineralsabaloparatideParathyroid Hormone-Related ProteinProcollagen Type ICollagen Type I

Autor:innen und Institutionen

  • New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.
  • Krakow Medical Center, Krakow, Poland.
  • United Osteoporosis Centers, Gainesville, GA, USA.
  • SOMED, Łódź, Poland.
  • Integral Rheumatology & Immunology Specialist (IRIS), Plantation, FL, USA.
  • Carteret Medical Group, Morehead City, NC, USA.

ORCID-Profile: E Michael Lewiecki, Neil Binkley, Bruce Mitlak

Förderung

  • Radius Health, Inc
  • Radius Health

Zitieren

APA

Lewiecki, E. M., Czerwinski, E., Recknor, C., Strzelecka, A., Valenzuela, G., Lawrence, M., Silverman, S., Cardona, J., Nattrass, S. M., Binkley, N., Annett, M., Pearman, L., & Mitlak, B. (2023). Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.4877

Vancouver

Lewiecki EM, Czerwinski E, Recknor C, Strzelecka A, Valenzuela G, Lawrence M, et al. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study. Journal of Bone and Mineral Research. 2023. doi:10.1002/jbmr.4877

BibTeX
@article{Lewiecki2023,
  author = {Lewiecki, E Michael and Czerwinski, Edward and Recknor, Chris and Strzelecka, Anna and Valenzuela, Guillermo and Lawrence, Mary and Silverman, Stuart and Cardona, Jose and Nattrass, Susan M and Binkley, Neil and Annett, Miriam and Pearman, Leny and Mitlak, Bruce},
  title = {Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study},
  journal = {Journal of Bone and Mineral Research},
  year = {2023},
  doi = {10.1002/jbmr.4877}
}
Kostenlos starten →